In mid-August, Novartis (NYSE: NVS) shared positive results from the phase 3 clinical trial of its biosimilar to Regeneron (NASDAQ: REGN) and Bayer AG's (OTC: BAYR.Y) Eylea. The Swiss drugmaker's results from the phase 3 clinical trial of its Eylea biosimilar suggest that it could be helpful in treating patients with age-related macular degeneration and diabetic macular edema.

With Novartis just months away from filing for regulatory approval for its biosimilar candidate, what could these results mean for the company financially? Let's take a closer look at the phase 3 clinical trial and Eylea's sales to get an answer.

Age-related macular degeneration (AMD) and diabetic macular edema (DME) are two common conditions that impact the eye. It's estimated that AMD affects over 200 million people around the world and is one of the most common causes of blindness. DME may also impact 21 million people.

Continue reading

Source Fool.com